Prestige Consumer Healthcare Completes $1.045B Breathe Right Acquisition, Secures New Term Loan
PBH is trading near its 52-week low of $42.62 (12% above the low).
Summary
Prestige Consumer Healthcare finalized its $1.045 billion acquisition of the Breathe Right® brand, financing it with a new $1.045 billion term loan and an amended $225 million ABL credit facility.
Key Events · M&A and Partnerships · PBH
-
Acquisition Completed
Prestige Consumer Healthcare completed the acquisition of the Breathe Right® brand and other assets for $1.045 billion in cash. This acquisition was previously announced on March 20, 2026, and its completion was reported in news on June 15, 2026.
-
New Term Loan Facility Secured
The company secured a new $1.045 billion Term Loan Credit Agreement to finance the Breathe Right acquisition. The loan bears interest at Term SOFR plus 2.00% and requires quarterly amortization payments.
-
ABL Credit Agreement Amended
The company's asset-based revolving line of credit was amended, increasing aggregate commitments to $225 million and extending its maturity date by five years, enhancing financial flexibility.
-
Future Acquisition Financing
The new Term Loan Credit Agreement also permits an uncommitted second draw of up to $95.0 million to partially finance the previously announced LaCorium Health acquisition, expected to close in Q2 FY27.
Analysis · PBH · Life Sciences
This 8-K confirms the completion of Prestige Consumer Healthcare's previously announced $1.045 billion acquisition of the Breathe Right® brand. To finance this significant transaction, the company has entered into a new $1.045 billion Term Loan Credit Agreement, substantially increasing its debt obligations. Additionally, the company amended its ABL Credit Agreement, increasing commitments and extending its maturity, which provides enhanced liquidity.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 36.9% of the 964 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.65%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PBH was trading at $47.87 on NYSE in the Life Sciences sector, with a market capitalization of approximately $2.2B. The 52-week trading range was $42.62 to $85.29. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.